fashion -WSS

fashion

author：hotspot 2025-09-30 05:03:39 - browse：3

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Will General Catalyst be the first of many hospital takeovers?

WSS

Ambulance rides for just $100? Advisers want major billing fixes

Experts study whether long Covid risk adds up with each reinfection

Will General Catalyst be the first of many hospital takeovers?

Extreme heat events are a public health emergency

6 solutions to address cancer drug shortages and others

What will Novo Nordisk's VC do with its influx of cash?

entertainment

fashion

entertainment

The high cost of giving birth even with insurance

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

DIEP, the 'gold standard' of breast reconstruction, is under threat

6 solutions to address cancer drug shortages and others

Hepatitis C has a cure — but many Americans still lack access to it

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

As demand for Covid shots wanes, Moderna seeks its next success

What will Novo Nordisk's VC do with its influx of cash?

Jerome Adams on the need for new antivirals for Covid

What will Novo Nordisk's VC do with its influx of cash?

hotspot

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Excited delirium, Elijah McClain, and emergency physicians

Study: New antibiotic targets gonorrhea as well as last existing drug

2023 Nobel Prize in Medicine goes to Karikó and Weissman

The Karikó problem: Lessons for funding basic research

explore

explore

leisure time

entertainment